Pro Medicus Growth Not Expected to Be Impeded by Artificial Intelligence, Jefferies Says

MT Newswires Live
07/09

Pro Medicus' (ASX:PME) growth is not expected to be impeded by artificial intelligence, but at the current share price, the market seems to be assuming that the firm will have a market share of the US picture archiving and communication system (PACS) market of around 51% by fiscal year 2035, from 11%, according to a Thursday note by Jefferies.

The firm's Visage PACS demonstrates class-leading low latency, which continues to drive market share gains. Large data sets, a shift to the cloud, and low growth in radiologists in the US are industry drivers over the medium-term.

AI is more likely to enhance Visage's value proposition because of its server-side streaming architecture, enterprise imaging "one viewer" strategy, and its cloud partnerships.

The investment firm downgraded Pro Medicus to hold from buy and raised the price target to AU$192.60 per share from AU$147 per share.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10